Drugs Made In America Acquisition (DMAAR) Income towards Parent Company (2025)
Drugs Made In America Acquisition (DMAAR) posted Income towards Parent Company of $212958.0 for Q4 2025, down 90.25% on a QoQ basis from $2.2 million in Q3 2025.
Drugs Made In America Acquisition (DMAAR) Income towards Parent Company (2025) Analysis & Trends
Drugs Made In America Acquisition's Income towards Parent Company history runs 1 years deep, the most recent figure standing at $212958.0 for Q4 2025.
- Quarterly Income towards Parent Company changed N/A year-over-year to $212958.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.9 million (changed N/A YoY) and the FY2025 annual result came in at $5.9 million, up 2222.83% from the prior year.
- Income towards Parent Company was $212958.0 for Q4 2025 at Drugs Made In America Acquisition, down from $2.2 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $2.3 million in Q2 2025 and bottomed at $212958.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | SIM Acquisition Corp. I | 314.52 Mn | 314.52 Mn | - |
| 2 | Thayer Ventures Acquisition | 208.29 Mn | 208.29 Mn | - |
| 3 | Newbury Street II Acquisition | 185.26 Mn | 185.26 Mn | - |
| 4 | Dynamix | 179.36 Mn | 179.36 Mn | - |
| 5 | Hallmark Venture | 103.01 Mn | 102.76 Mn | - |
| 6 | Voyager Acquisition | 99.58 Mn | 99.45 Mn | - |
| 7 | Gores Holdings X | 95.80 Mn | 95.37 Mn | - |
| 8 | Archimedes Tech SPAC Partners | 89.63 Mn | 89.63 Mn | - |
| 9 | Marblegate Capital | 81.65 Mn | 55.81 Mn | - |
| 10 | Drugs Made In America Acquisition | 1.37 Mn | 1.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 212,958.00 |
| Sep 30, 2025 | 2.18 Mn |
| Jun 30, 2025 | 2.29 Mn |
| Mar 31, 2025 | 1.25 Mn |